SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
A phase 2 trial of Trastuzumab duocarmazine in Endometrial cancer, run by Byondis B.V., completed.
Overview
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma is a phase 2 interventional study registered as NCT04205630 by Byondis B.V., with 64 participants recorded, started 2020-05-28 and reaching its primary completion in 2023-01-26. Interventions recorded: SYD985. Conditions recorded: Endometrial Cancer.
Linked to the drug Trastuzumab duocarmazine because the registry names it among its interventions and Endometrial cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialSYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
Shares Byondis, Trastuzumab duocarmazine and the tag pipeline.
- TrialTreatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer
Shares Endometrial cancer and the tag pipeline.
- TrialMirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer
Shares Endometrial cancer and the tag pipeline.
- TrialValue of LNG-IUS as Fertility-preserving Treatment of EAH and EC
Shares Endometrial cancer and the tag pipeline.
- TrialA Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Shares Endometrial cancer and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer and the tag pipeline.
- TrialPsilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Shares Endometrial cancer and the tag pipeline.